

Pharmaceutical Services, 2 Franklin Street, Belfast BT2 8DQ Telephone No. 028 95 36 0333

UPDATE: Updates to communication (MPS 3386) issued 16 June 2025 in bold

## Medicine Supply Notification:


Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and Levemir® (insulin detemir) Penfill 100units/ml solution for injection 3ml cartridges
Tier 2 – medium impact

Date of issue: 14/08/2025

<u>Medicines Supply Tool – SPS - Specialist Pharmacy Service – The first stop for professional medicines advice</u>

# Summary

- Levemir® (insulin detemir) FlexPen® 100units/ml solution for injection 3ml pre-filled pens and Levemir® (insulin detemir) Penfill® 100units/ml solution for injection 3ml cartridges are being discontinued; stock is anticipated to be exhausted by the end of 2026.
- Clinical guidance has been produced by clinical experts (see Supporting information).
- Current supply positions and ability of alternative insulins to support an increase in demand is summarised below. Any changes to availability will be communicated via the SPS Medicines Supply Tool.



# Actions Required

#### Clinicians should:

- not initiate new patients on any Levemir® product; and
- begin implementing insulin switches for all existing Levemir® patients in line with the clinical guidance (see Supporting information).

Local teams should avoid initiating widespread switches without checking the current supply overview of alternative insulins to reduce the risk of precipitating a supply disruption of these products (see Supporting information).

As recommended in the <u>clinical guidance</u>, clinicians should aim to diversify prescribing across available alternatives to reduce supply risk where possible.

In addition to consulting the <u>clinical guidance</u>, when prescribing alternatives, consider manual dexterity, vision, and whether additional support is required for administration, and:

- ensure that all patients/carers are counselled on dose to be administered, provided with training on the use of their new device, as well as appropriate ancillaries, including signposting to training videos; and
- advise patients that closer monitoring of blood glucose levels is required initially, and their insulin dose may need to be adjusted.

Seek advice from specialist diabetes teams where required.

**OFFICIAL-SENSITIVE** 

# Supporting information

## **Supply summary table**

Levemir is a long-acting insulin analogue with a prolonged duration of effect used as a basal insulin. It is licensed for the treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above. It can be used alone as the basal insulin or in combination with bolus insulin. It can also be used in combination with oral antidiabetic medicinal products and/or GLP-1 receptor agonists.

As insulin glargine is available in two strengths, these products must be prescribed BY BRAND to minimise the risk of product mis-selection.



Insulin type		Supply overview	
Insulin type	Brand name and devices	Stock status	Ability to support increased demand
Insulin glargine U100 (Long acting)	Abasaglar® KwikPen®	In stock	Cannot support
	Abasaglar <sup>®</sup> cartridges	In stock	Cannot support
	Lantus <sup>®</sup> SoloStar <sup>®</sup>	In stock	Can support
	Lantus <sup>®</sup> cartridges	In stock	Can support
	Semglee <sup>®</sup> pre-filled pens (biosimilar)	In stock	Can support
Insulin glargine U300 (Ultralong acting)	Toujeo <sup>®</sup> SoloStar <sup>®</sup>	In stock	Can support
	Toujeo <sup>®</sup> DoubleStar <sup>®</sup>	In stock	Can support
Insulin degludec (Ultralong acting)	Tresiba <sup>®</sup> U100 FlexTouch <sup>®</sup>	Out of stock until early January 2026	Cannot support
	Tresiba <sup>®</sup> U100 cartridges	In stock	Can support
	Tresiba <sup>®</sup> U200 FlexTouch <sup>®</sup>	In stock	Can support
Human isophane insulin (intermediate acting)	Humulin I <sup>®</sup> KwikPen <sup>®</sup>	In stock	Cannot support
	Humulin I <sup>®</sup> cartridges	In stock	Cannot support

### Links to further information

Clinical Guideline: Discontinuation of Levemir®

**BNF Insulin detemir** 

**BNF** Insulin preparations

NICE guidance: Type 1 diabetes in adults (insulin therapy)

NICE CKS- Insulin therapy in type 1 diabetes

NICE CKS- Insulin therapy in type 2 diabetes

SmPC Levemir®

SmPC Lantus®

SmPC Toujeo®

SmPC Abasaglar®

SmPC Semglee®

SmPC Tresiba®

SmPC Humulin® I

SPS Medicines Supply Tool - Shortage of Tresiba (insulin degludec) FlexTouch 100units/ml solution for injection 3ml pre-filled pens